NEW YORK (GenomeWeb News) – Synthetic biology firm Intrexon has filed to raise up to $125 million in an initial public offering.

The Germantown, Md.-based firm has not yet determined a price range on its shares, and it didn't disclose in its Form S-1 filed with the US Securities Exchange on Tuesday how many shares it plans to offer. JP Morgan and Barclays will be joint book-running managers on the offering.

Intrexon plans to list on the New York Stock Exchange under ticker symbol "XON".

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.